SUN-247 Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Efficacy and Safety Results of a Randomized, Open-Label, Controlled Phase 2 Trial (REAL 3)

Background: Growth hormone deficiency (GHD) requires long-term daily injections with GH replacement therapy and is associated with considerable treatment burden. Somapacitan is a long-acting GH derivative being developed for once-weekly dosing in adults and children with GHD. A well-established prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Savendahl, Lars, Højby Rasmussen, Michael, Horikawa, Reiko, Khadilkar, Vaman, Battelino, Tadej, Saenger, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552843/
http://dx.doi.org/10.1210/js.2019-SUN-247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552843/
http://dx.doi.org/10.1210/js.2019-SUN-247

Ejemplares similares